Entia Biosciences Stock Probability of Future Pink Sheet Price Finishing Under 1.22E-4
| ERGO Stock | USD 0.0002 0.00 0.00% |
Entia |
Entia Biosciences Target Price Odds to finish below 1.22E-4
The tendency of Entia Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.0001 or more in 90 days |
| 0.0002 | 90 days | 0.0001 | about 14.29 |
Based on a normal probability distribution, the odds of Entia Biosciences to drop to $ 0.0001 or more in 90 days from now is about 14.29 (This Entia Biosciences probability density function shows the probability of Entia Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Entia Biosciences price to stay between $ 0.0001 and its current price of $2.0E-4 at the end of the 90-day period is about 59.23 .
Given the investment horizon of 90 days Entia Biosciences has a beta of -3.14 suggesting as returns on its benchmark rise, returns on holding Entia Biosciences are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Entia Biosciences is expected to outperform its benchmark. Moreover Entia Biosciences has an alpha of 1.8648, implying that it can generate a 1.86 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Entia Biosciences Price Density |
| Price |
Predictive Modules for Entia Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Entia Biosciences. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Entia Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Entia Biosciences is not an exception. The market had few large corrections towards the Entia Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Entia Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Entia Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.86 | |
β | Beta against Dow Jones | -3.14 | |
σ | Overall volatility | 0.000046 | |
Ir | Information ratio | 0.11 |
Entia Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Entia Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Entia Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Entia Biosciences is way too risky over 90 days horizon | |
| Entia Biosciences has some characteristics of a very speculative penny stock | |
| Entia Biosciences appears to be risky and price may revert if volatility continues | |
| Entia Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company has a current ratio of 0.11, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Entia Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Entia Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entia Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entia to invest in growth at high rates of return. When we think about Entia Biosciences' use of debt, we should always consider it together with cash and equity. | |
| Entia Biosciences reported the previous year's revenue of 265.47 K. Net Loss for the year was (1.4 M) with profit before overhead, payroll, taxes, and interest of 173.97 K. | |
| Entia Biosciences currently holds about 76.05 K in cash with (715.1 K) of positive cash flow from operations. | |
| Latest headline from finance.yahoo.com: Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa |
Entia Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Entia Pink Sheet often depends not only on the future outlook of the current and potential Entia Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Entia Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 24.3 M | |
| Cash And Short Term Investments | 76 K |
Entia Biosciences Technical Analysis
Entia Biosciences' future price can be derived by breaking down and analyzing its technical indicators over time. Entia Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Entia Biosciences. In general, you should focus on analyzing Entia Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Entia Biosciences Predictive Forecast Models
Entia Biosciences' time-series forecasting models is one of many Entia Biosciences' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Entia Biosciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Entia Biosciences
Checking the ongoing alerts about Entia Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Entia Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Entia Biosciences is way too risky over 90 days horizon | |
| Entia Biosciences has some characteristics of a very speculative penny stock | |
| Entia Biosciences appears to be risky and price may revert if volatility continues | |
| Entia Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company has a current ratio of 0.11, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Entia Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Entia Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entia Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entia to invest in growth at high rates of return. When we think about Entia Biosciences' use of debt, we should always consider it together with cash and equity. | |
| Entia Biosciences reported the previous year's revenue of 265.47 K. Net Loss for the year was (1.4 M) with profit before overhead, payroll, taxes, and interest of 173.97 K. | |
| Entia Biosciences currently holds about 76.05 K in cash with (715.1 K) of positive cash flow from operations. | |
| Latest headline from finance.yahoo.com: Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa |
Other Information on Investing in Entia Pink Sheet
Entia Biosciences financial ratios help investors to determine whether Entia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Entia with respect to the benefits of owning Entia Biosciences security.